EPIC-GB: New Clinical Trials Aim to Transform Glioblastoma Treatment in Yorkshire
A significant breakthrough in the fight against brain cancer is arriving in Yorkshire. A £6.9 million clinical trial programme, known as EPIC-GB, has been launched to improve survival rates and quality of life for patients battling glioblastoma, the most common and fastest-growing type of brain cancer.
- The Goal: To transform how cancer drug effectiveness is tested for people with recurrent glioblastoma.
- The Funding: The £6.9 million project is funded by Yorkshire Cancer Research.
- The Locations: Trials will be delivered across Sheffield, Leeds, and Hull.
- The Innovation: Patients will start trial treatments before surgery to allow for direct study of drug penetration into the tumour.
Understanding the Challenge: Why Glioblastoma is Hard to Treat
Glioblastoma is an aggressive form of brain cancer. In Yorkshire alone, approximately 247 people are diagnosed with the disease each year, and about 181 people die. For many, the cancer returns within the first year after initial treatment.
One of the primary obstacles in treating this cancer is the blood-brain barrier. This protective layer around the brain often prevents many existing cancer drugs from reaching the tumours. According to BBC News, this challenge has contributed to a lack of significant breakthroughs in glioblastoma treatment for nearly 20 years.
How the EPIC-GB Trials Operate
The EPIC-GB programme, led by experts from the University of Sheffield and the University of Glasgow, introduces a “window of opportunity” approach to testing drugs. Instead of the traditional sequence, participants will start new treatments before undergoing surgery.
The “Window of Opportunity” Process:
- Pre-Surgical Treatment: Patients receive trial drugs before their operation.
- Tissue Analysis: When surgeons remove the tumour, the tissue is studied to see if the drugs successfully crossed the blood-brain barrier and reached the tumour.
- Rapid Adjustment: By identifying which drugs are ineffective early on, doctors can drop them quickly to avoid unnecessary side effects and switch patients to more promising options faster.
Bringing Hope to the Region
For patients in Yorkshire, where survival rates have historically been lower than the national average, these trials offer a critical lifeline. Emma Ward, a 47-year-ancient from York diagnosed with a fast-growing tumour in 2025, emphasized that research is the only way to give families more time together. Facing limited local options, Ward previously had to raise £145,000 from friends and family to travel abroad for immunotherapy treatment.
Frequently Asked Questions
What is glioblastoma?
Glioblastoma is the most common and fastest-growing type of brain cancer. It is characterized by its aggressive nature and frequent recurrence.
Where can patients access these trials?
The EPIC-GB trials will be delivered in Sheffield, Leeds, and Hull.
Who is leading the research?
The programme is led by experts at the University of Sheffield and the University of Glasgow and is funded by Yorkshire Cancer Research.
Looking Ahead
By refining the way drug effectiveness is measured, EPIC-GB aims to accelerate the discovery of life-extending treatments. This shift toward personalized, evidence-based drug testing could provide a blueprint for treating other difficult-to-reach tumours in the brain, offering new hope to patients and their families across the UK.